Transient Receptor Potential Vanilloid 1 is Essential for Cisplatin-Induced Heat Hyperalgesia in Mice

Molecular Pain - Tập 6 - Trang 1744-8069-6-15 - 2010
Lauren E. Ta1,2, Allan J. Bieber1,2, Susan M. Carlton3, Charles L. Loprinzi4, P. A. Low5, Anthony J. Windebank1,2
1Department of Neuroscience, Mayo Clinic, College of Medicine, Rochester, MN 55905, USA
2Program in Molecular Neuroscience, Mayo Graduate School, Mayo Clinic, College of Medicine, Rochester, MN 55905, USA
3Department of Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX 77555, USA
4Division of Medical Oncology, Mayo Clinic, College of Medicine, Rochester, MN 55905, USA
5Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA

Tóm tắt

Background: Cisplatin is primarily used for treatment of ovarian and testicular cancer. Oxaliplatin is the only effective treatment for metastatic colorectal cancer. Both are known to cause dose related, cumulative toxic effects on the peripheral nervous system and thirty to forty percent of cancer patients receiving these agents experience painful peripheral neuropathy. The mechanisms underlying painful platinum-induced neuropathy remain poorly understood. Previous studies have demonstrated important roles for TRPV1, TRPM8, and TRPA1 in inflammation and nerve injury induced pain. Results: In this study, using real-time, reverse transcriptase, polymerase chain reaction (RT-PCR), we analyzed the expression of TRPV1, TRPM8, and TRPA1 induced by cisplatin or oxaliplatin in vitro and in vivo. For in vitro studies, cultured E15 rat dorsal root ganglion (DRG) neurons were treated for up to 48 hours with cisplatin or oxaliplatin. For in vivo studies, trigeminal ganglia (TG) were isolated from mice treated with platinum drugs for three weeks. We show that cisplatin and oxaliplatin-treated DRG neurons had significantly increased in TRPV1, TRPA1, and TRPM8 mRNA expression. TG neurons from cisplatin treated mice had significant increases in TRPV1 and TRPA1 mRNA expression while oxaliplatin strongly induced only TRPA1. Furthermore, compared to the cisplatin-treated wild-type mice, cisplatin-treated TRPV1-null mice developed mechanical allodynia but did not exhibit enhancement of noxious heat- evoked pain responses. Immunohistochemistry studies showed that cisplatin-treated mice had no change in the proportion of the TRPV1 immunopositive TG neurons. Conclusion: These results indicate that TRPV1 and TRPA1 could contribute to the development of thermal hyperalgesia and mechanical allodynia following cisplatin-induced painful neuropathy but that TRPV1 has a crucial role in cisplatin-induced thermal hyperalgesia in vivo.

Từ khóa


Tài liệu tham khảo

10.1111/j.1529-8027.2008.00156.x

10.1002/1097-0142(197405)33:5<1219::AID-CNCR2820330505>3.0.CO;2-U

10.1016/0305-7372(89)90041-8

10.1056/NEJMoa032709

10.1200/JCO.2004.05.113

Petrioli R, 2008, Cancer Chemother Pharmacol, 1, 105

10.1021/cr068207j

Eastman A, 1990, Cancer Cells, 8, 275

10.1038/21460

10.1097/00019052-199910000-00010

10.1007/PL00007853

10.1016/S0014-4886(03)00003-7

10.1016/j.pain.2006.09.016

10.1016/j.lfs.2007.06.012

10.1210/en.2007-0828

Rodriguez-Menendez V, 2008, Anticancer Res, 1, 335

10.1016/j.tox.2007.02.013

10.1016/j.jpain.2008.01.335

10.1038/nrn1141

10.1126/science.288.5464.306

10.1038/35012076

10.1016/S0896-6273(04)00150-3

10.1038/nature02282

10.1073/pnas.0505356102

10.1016/j.cell.2006.02.023

10.1073/pnas.0609598103

10.1038/nchembio821

10.1073/pnas.0705923104

10.1523/JNEUROSCI.5369-07.2008

10.1111/j.1460-9568.2008.06093.x

10.1016/S0092-8674(03)00158-2

10.1016/j.neuron.2006.03.042

10.1172/JCI25437

10.1016/j.expneurol.2006.01.031

10.1523/JNEUROSCI.0013-05.2005

10.1016/S0092-8674(02)00652-9

10.1016/j.neuron.2007.04.017

10.1016/j.neuron.2007.02.024

10.1046/j.0953-816x.2001.01591.x

10.1124/jpet.103.050948

10.1074/jbc.M511072200

10.1016/j.bbrc.2007.05.029

Ta LE, 2009, Mol Pain, 9

10.1016/j.nbd.2004.09.013

10.1016/j.neuro.2006.04.010

10.1172/JCI1130

10.1016/0024-3205(94)00744-6

10.1212/WNL.44.3_Part_1.488

10.1016/0041-008X(92)90156-M

10.1016/0006-8993(95)00100-5

10.1016/j.neulet.2009.04.029

10.1038/379257a0

10.1016/j.ceca.2006.07.008

Zimmermann K, 2007, Nature, 7146, 855

10.1523/JNEUROSCI.4778-08.2009

10.1073/pnas.0705924104

Eid SR, 2008, Mol Pain, 48

Kerstein PC, 2009, Mol Pain, 19

10.1523/JNEUROSCI.5380-08.2009

Petrus M, 2007, Mol Pain, 40

10.1038/nrd2757

10.1016/j.neulet.2008.04.007

10.1038/414813a

10.1038/ncpneuro0320

10.1016/S0896-6273(00)81003-X

10.1016/j.npep.2005.10.004

10.1016/S0304-3940(01)02093-6

10.1016/S0006-8993(02)03972-0

10.1016/0014-4886(88)90157-4

10.1016/S0959-8049(01)00300-8

10.1016/S0093-7754(03)00399-3

10.1016/0006-8993(89)91293-6

10.1124/jpet.102.042010

10.1016/j.pain.2005.06.024

10.1523/JNEUROSCI.3815-04.2005

10.1016/j.pain.2005.03.010

10.1038/nrd2280

10.1016/0304-3959(83)90201-4

10.1006/meth.2001.1262

Thông tin
Thông tin xuất bản

Molecular Pain

Tập 6

1744-8069-6-15

Thông tin tác giả